logo
Select company
Select metric
$ 36.76MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
48
Sector
81
Industry
93
History
100
$ 10.05Close
$ 3.7 - $ 11.11 52-Week Range
Ticker Information

Ticker

GLUE

Company Name

MONTE ROSA THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

MONTE ROSA THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

GLUE - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 8.34M$ 28.42M$ 36.76M
3/31/2025$ 8.27M$ 9.46M$ 17.73M
12/31/2024$ 8.12M$ -70.13M$ -62.01M
9/30/2024$ 7.91M$ -119M$ -111.1M
6/30/2024$ 7.64M$ -129.93M$ -122.29M
3/31/2024$ 6.97M$ -134.86M$ -127.89M
12/31/2023$ 6.22M$ -135.01M$ -128.79M
9/30/2023$ 7.06M$ -132.52M$ -125.46M
6/30/2023$ 7.8M$ -125.13M$ -117.33M
3/31/2023$ 8.58M$ -116.61M$ -108.03M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • MONTE ROSA THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -35.33M.
  • Over the past 5 years, MONTE ROSA THERAPEUTICS INC's average EBITDA has been $ -82.6M.
  • The median EBITDA for MONTE ROSA THERAPEUTICS INC during this period was $ -97.21M
  • MONTE ROSA THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ 36.76M.
  • The lowest EBITDA recorded by MONTE ROSA THERAPEUTICS INC in the same timeframe $ -128.79M

MONTE ROSA THERAPEUTICS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
VNDA : VANDA PHARMACEUTICALS INC $ -77.06MHRTX : HERON THERAPEUTICS INC $ 3.88MARCT : ARCTURUS THERAPEUTICS HOLDINGS INC $ -72.27MCTMX : CYTOMX THERAPEUTICS INC $ 54.08MRGNX : REGENXBIO INC $ -129.93MMGNX : MACROGENICS INC $ -28.01MTRDA : ENTRADA THERAPEUTICS INC $ -73MPBYI : PUMA BIOTECHNOLOGY INC $ 63.29MCDXS : CODEXIS INC $ -46.09MSCPH : SCPHARMACEUTICALS INC $ -85.42M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for MONTE ROSA THERAPEUTICS INC is calculated as follows: EBIT [ $ -35.87M ] + DepAmor [ $ 537K ]
(=) EBITDA [ $ -35.33M ]

GLUE - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -128.79M

Minimum

Dec 31, 2023

$ 36.76M

Maximum

Jun 30, 2025

$ -82.6M

Average

$ -97.21M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M